Pfizer plans to develop future mRNA vaccines and therapies on its own without BioNTech.
Acquiring a small biotech with mRNA expertise could help Pfizer achieve its goals.
There's one such biotech that also would give it two promising immunotherapy candidates and a solid platform for developing vaccines and immunotherapies targeting a wide range of diseases.
